Paris (France), -– IMSTAR is pleased to announce the recent collaboration with Japan Tobacco Inc. (JTI) following the set-up of its Pathfinder™ Screentox Auto Micronucleus Image Cytometer System for in vitro/in vivo genetic toxicology studies at JTI’s Research Center near Tokyo.

Japan Tobacco Inc. (JTI) will apply Pathfinder™ Screentox technology for automated scoring of micronucleus test in different cell types. The use of this capability will add value by enhancing test accuracy and reliability. In addition, the versatility of this system will lay the foundation for the potential development of a new technical framework in the field of genetic toxicology studies applied to the tobacco industry.

“We are very happy about our new collaboration with Japan Tobacco Inc. It is our understanding that JTI looked at several alternatives and chose IMSTAR for its long-standing, recognised expertise”, said Françoise Soussaline, IMSTAR’s President and CEO. “We have been at the forefront of the development of in vitro toxicology tests for years, not only in terms of their automation but also in terms of their scientific basis and standardization. Adding JTI to our list of customers validates further is a further validation of our approach and our products”.

About IMSTAR S.A.

IMSTAR (Paris, France) is a high-technology company offering comprehensive solutions for automated, quantitative and cost effective Image Cytometer based on its proprietary Pathfinder™ technology. IMSTAR services its customers in the fields of cytopathology, cytogenetic, genetic and environmental toxicity, applied to a large range of tests for preclinical research, bio-monitoring and drug safety amongst others.

Itsteam includes multidisciplinary experts in various fields: automated systems, biophysics, physics, applied mathematics, cellular biology and cytopathology. Over 1000 Pathfinder™ systems have been installed in the world to date, including Europe, North America and Asia.

Learn more: https://www.imstarsa.com/